[1]魏海东,王晓平,万毅新,等.康艾注射液联合NP方案治疗非小细胞肺癌50例疗效观察[J].西部中医药,2012,25(09):57-59.
　WEI Hai-dong,WANG Xiao-ping,WAN Yi-xin,et al.Kang′ai Injection and NP Therapy in the Treatment for 50 Cases of Non-Small-Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(09):57-59.
点击复制

康艾注射液联合NP方案治疗非小细胞肺癌50例疗效观察

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
25
期数:
2012年09期
页码:
57-59
栏目:
出版日期:
2012-09-15

文章信息/Info

Title:
Kang′ai Injection and NP Therapy in the Treatment for 50 Cases of Non-Small-Cell Lung Cancer
文章编号:
1004-6852(2012)09-0057-03
作者:
魏海东，王晓平，万毅新，王虹，陶红艳，黄晖蓉，李芳伟，武凡祺，张丽
兰州大学第二医院呼吸科，甘肃 兰州 730030
Author(s):
WEI Hai-dong, WANG Xiao-ping, WAN Yi-xin, WANG Hong, TAO Hong-yan,HUANG Hui-rong, LI Fang-wei, WU Fan-qi, Zhang Li
Pulmonary Department of Lanzhou University Second Hospital, Lanzhou 730030, China
关键词:
非小细胞肺癌; 康艾注射液; TP方案
Keywords:
non-small-cell lung cancer;  Kang′ai injection;  NP therapy
分类号:
R734.2
文献标志码:
B
摘要:
目的：观察康艾注射液联合NP方案治疗非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法：将100例NSCLC患者随机分为对照组和观察组各50例。2组均采用NP方案进行化疗，观察组在对照组治疗基础上加用康艾注射液，比较2组的近期疗效及不良反应。结果：近期临床总有效率观察组为44.0%，对照组为38.0%，2组相比差异无统计学意义(P＞0.05)；观察组生存质量显著提升，白细胞减少发生率显著降低，组间差异具有统计学意义(P＜0.05)。结论：康艾注射液在NSCLC化疗过程中具有增效减毒、改善生存质量的作用。
Abstract:
Objective: To explore clinical effects and adverse reactions of Kang′ai injection and NP therapy in the treatment of non-small-cell lung cancer(NSCLC). Method: One hundred patients were randomly divided into observation group and control group equally. Both groups received NP therapy, observation group were also administered with Kang′ai injection. Curative effects in near future and adverse reaction of both groups were compared. Result: Total effective rate of observation group was 44.0%, higher than 38.0% of control group without statistical meaning(P＞0.05); life quality raised remarkably and incidence of leukocyte reduction decreased obviously in observation group, comparisons between both groups showed remarkable difference and the difference indicated statistical meaning (P＜0.05). Conclusion: Kang′ai injection can raise the efficacy, reduce the toxicity and improve life quality during the course of chemotherapy.

相似文献/References:

[1]宋春燕,王翠英.参芎葡萄糖联合放疗治疗局部晚期非小细胞肺癌50例临床观察[J].西部中医药,2013,26(01):89.
　SONG Chunyan,WANG Cuiying.Clinical Observation on ShenXiong Glucose Combined with Radiotherapy for 50 Cases of Local Non-small-cell Lung Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(09):89.
[2]席彩霞,杨国泉,苏安平,等.贞芪益气胶囊联合 GP 方案治疗晚期非小细胞肺癌的临床研究[J].西部中医药,2014,27(09):4.
[3]廖绛阳,张红△.血府逐瘀汤加味配合γ-刀治疗气虚血瘀证中晚期非小细胞肺癌30例[J].西部中医药,2015,28(10):98.
[4]宋春燕,王翠英.康艾注射液联合顺铂热灌注治疗恶性胸腹腔积液80例[J].西部中医药,2013,26(06):87.
　SONG Chunyan,WANG Cuiying.KangAi Injection and Cisplatin Perfusion for 80 Cases of Malignant Pleural Effusions and Ascites[J].Western Journal of Traditional Chinese Medicine,2013,26(09):87.
[5]郭继龙,李斌,李亚玲,等.益气养阴汤联合化疗治疗气阴两虚型中晚期非小细胞肺癌30例[J].西部中医药,2017,30(08):84.
　GUO Jilong,LI Bin,LI Yaling,et al.Qi-tonifying Yin-nourishing Decoction Combined with Chemotherapy in Treating 30 Cases of Advanced Non Small-cell Lung Cancer of Dual Deficiency Pattern of Qi-Yin[J].Western Journal of Traditional Chinese Medicine,2017,30(09):84.
[6]孙华,李祖隆,洪晓华,等.miRNA调控NSCLC血管生成及中医药干预机制的研究进展[J].西部中医药,2026,39(03):141.[doi:10.12174/j.issn.2096-9600.2026.03.26]
　SUN Hua,LI Zulong,HONG Xiaohua,et al.Research Progress on the Regulation of Angiogenesis by miRNA in NSCLC and the Intervention Mechanisms of Traditional Chinese Medicine[J].Western Journal of Traditional Chinese Medicine,2026,39(09):141.[doi:10.12174/j.issn.2096-9600.2026.03.26]
[7]朱小英.舒适化护理在非小细胞肺癌化疗患者中的应用效果评价[J].西部中医药,2019,32(08):133.
　ZHU Xiaoying.Effects Evaluation of Comfortable Nursing Applied to NSCLC Patients Undergoing Chemotherapy[J].Western Journal of Traditional Chinese Medicine,2019,32(09):133.
[8]沈倩芸,李和根.中西医结合治疗570例晚期非小细胞肺癌回顾性生存分析及队列研究[J].西部中医药,2025,38(11):134.[doi:10.12174/j.issn.2096-9600.2025.11.24]
　SHEN Qianyun,LI Hegen.Retrospective Survival Analysis and Cohort Studies on 570 Cases of Advanced NSCLC Treated with Integrative Traditional Chinese and Western Medicine[J].Western Journal of Traditional Chinese Medicine,2025,38(09):134.[doi:10.12174/j.issn.2096-9600.2025.11.24]
[9]田琳,毕胜男,陈梦竹,等.基于网络药理学探索血府逐瘀汤治疗非小细胞肺癌的作用机制[J].西部中医药,2022,35(01):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
　TIAN Lin,BI Shengnan,CHEN Mengzhu,et al.Research on the Mechanism of Xuefu Zhuyu Decoction in the Treatment of NSCLC Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(09):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
[10]刘爽,杨阳阳,魏巍.3-PR参与式健康教育在NSCLC患者护理中的应用[J].西部中医药,2022,35(02):137.[doi:10.12174/j.issn.2096-9600.2022.02.35]
　LIU Shuang,YANG Yangyang,WEI Wei.Application of 3-PR Participatory Health Education in the Care for NSCLC Patients[J].Western Journal of Traditional Chinese Medicine,2022,35(09):137.[doi:10.12174/j.issn.2096-9600.2022.02.35]

备注/Memo

备注/Memo:
收稿日期：2012-06-20 作者简介：魏海东(1976—)，男，硕士学位，主治医师。研究方向：肺部肿瘤的诊治。
更新日期/Last Update: 2012-09-15